Adriano Aguzzi

Has grant

Country flagSwitzerland

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Immunity to Coronavirus

Open Date: 2021-01-01

Close Date: 2022-12-01

Grant: Close

PrP and its receptor GPR126: guardians of axomyelinic integrity and druggable targets against demyelinating diseases

Open Date: 2019-02-01

Close Date: 2023-01-01

Grant: Close

The prion protein in health and disease

Open Date: 2018-06-01

Close Date: 2022-05-01

Grant: Close

Population-wide screens of the human immune repertoire: A reverse personalized-medicine approach

Open Date: 2018-01-01

Close Date: 2021-06-01

Grant: Close

Neuroprotective human antibodies to the flexible tail of the prion protein

Open Date: 2017-09-01

Close Date: 2019-02-01

Articles (29)

Year:

2026

Commensal bacteria play a crucial role in modulating human immune responses in the intestine. Under homeostatic conditions, gut microbiota are tightly regulated by interactions with the mucosal immune system. However, colorectal cancer (CRC) is characterized by an imbalance in bacterial composition and bacterial translocation across the intestinal barrier. The spatial distribution of bacteria and their interactions with immune cells in CRC tumors are poorly understood. By applying 3D light-sheet imaging, spatial transcriptomics, and imaging mass cytometry to patient-derived CRC and adjacent tissue, bacterial lipopolysaccharide (LPS) is visualized alongside immune cells and vessels. The results show regional bacterial LPS accumulation and colocalization with distinct immune cell subsets. In CRC-adjacent tissue, bacterial LPS is mainly associated with CD11c + dendritic cells, CD15 + neutrophils, and CD163 + macrophages. In matched CRC tissue, the number and LPS colocalization of CD163 + macrophages and CD11c + dendritic cells decreased, while CD15 + neutrophils and their colocalization with LPS increased. Notably, immune cell composition and immune cell-bacteria interactions differ between tumor and adjacent tissue, offering insights into host-microbiota dynamics and mechanistic interactions.

Year:

2026

Intraneuronal aggregates of the microtubule-associated protein tau play a pivotal role in Alzheimer’s disease and several other neurodegenerative syndromes. Anti-tau antibodies can reduce pathology in mouse models of neurodegeneration and are currently being tested in humans. Here, we performed a large-scale seroepidemiological search for anti-tau IgG autoantibodies (ατ) on 40,497 human plasma samples. High-titer ατ + individuals were surprisingly prevalent, with hospital patients being three times more likely to be ατ + (EC 50 ≥ 2 6 ; a nominal dilution of >1/64) than healthy blood donors (4.8% versus 1.6%). The prevalence increased with age over 70 years-old (RR 1.26, 95% CI 1.11–1.43, P < 0.001) and was higher for women (RR 1.20, 95% CI 1.07–1.39, P = 0.002). The autoantibodies bound selectively to tau, inhibited tau aggregation in vitro, and interfered with tau detection in plasma samples. No association was found between ατ autoantibodies and neurological disorders. Instead, tau autoreactivity showed a significant association with kidney and urinary disorders (adjusted RR 1.27, 95% CI 1.10–1.45, P = 0.001 and 1.40, 95% CI 1.20–1.63, P < 0.001, respectively). These results suggest a previously unrecognized association between ατ autoimmunity and extraneural diseases.

Year:

2025

Frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) shows striking clinical and neuropathological heterogeneity, yet a systematic analysis of subtype-specific features and inter-patient variability was missing. We treated human neurons and neuron-like cells with 30 postmortem brain samples and quantified neoaggregate formation, loss of function and changes in the TDP-43 interactome to define determinants of seeding outcomes. Potent FTLD-TDP-A seeds drove a progressive collapse of physiological TDP-43 interactions accompanied by functional loss. Beyond the burden of pathological TDP-43, we identified the fibrillar core of the lysosomal protein TMEM106B as a critical pro-seeding factor. Transient lysosomal injury markedly enhanced neoaggregation and loss of function, likely by promoting fibril interactions with native TDP-43. Our work establishes a mechanistic link between TMEM106B and TDP-43 aggregation, identifies lysosomal escape as a key driver of pathology and introduces the strongest model yet for seeded TDP-43 aggregation and loss of function, to enable discovery of disease modifiers.

Year:

2025

Prion diseases are transmissible neurodegenerative disorders caused by the spread of misfolded prion protein between cells and individuals, yet the paths by which prions colonize cells are undefined. Here we map the determinants of prion uptake with a genome-wide quadruple-guide CRISPR activation screen. Uptake of prions was measured by flow cytometry in PRNP -ablated human SHSY-5Y cells exposed to synthetic ovine prions. We identified 43 genes modulating prion uptake, 6 of which belonged to the core components of the Bone Morphogenetic Protein (BMP) signaling axis. Prion internalization was increased by overexpression of BMP receptors (BMPR1B, BMPR2, ACVRL1) and the Small Mothers Against Decapentaplegic (SMAD1 and SMAD5) intracellular BMP effectors, whereas the inhibitory SMAD6 reduced it. The internalization of other proteopathic seeds (α-synuclein, tau K18, amyloid-β) and other endocytic probes (transferrin, dextran, E. coli bioparticles) was unaffected. Transcriptional profiles of a panel of persistently prion-infected cell lines showed broad dysregulation of BMP-related signaling. Hence, BMP signaling is a gatekeeper of prion entry mechanistically distinct from bulk endocytosis and amyloid uptake. Chronic prion propagation induced SMAD1/5 phosphorylation, suggesting a positive-feedback loop during prion infection. The connection of prion uptake to a developmentally conserved morphogen pathway with rich pharmacology suggests that BMP signaling nodes may serve as tractable levers to modulate early events in prion transmission.

Year:

2025

The aggregation of the protein alpha-synuclein (αSyn) is a common feature of multiple neurodegenerative diseases collectively called synucleinopathies, for which the pathobiology is not well understood. The different phenotypic characteristics of the synucleinopathies Parkinson’s disease (PD), Dementia with Lewy Bodies (DLB) and Multiple System Atrophy (MSA) have been proposed to originate from the distinct structures adopted by αSyn in its amyloid forms. Here, using covalent labeling and limited proteolysis coupled to mass spectrometry (LiP-MS) in vitro and in situ within neuronal cells and directly in native patient brain homogenates, we show that pathogenic αSyn from distinct synucleinopathies (PD, DLB and MSA) are structurally different. Further, we found that fibrillar structural differences are associated with different fibril interactomes and neuronal responses. We discovered disease-specific ubiquitination patterns and turnover profiles for pathogenic αSyn species, detected molecular pathways responding specifically to the uptake of different αSyn fibrillar polymorphs, and identified a subset of the involved proteins as candidate direct interactors of αSyn. In particular, components of the Ubiquitin-proteasomal System (UPS), including E3 ubiquitin ligases, chaperones, and Deubiquitinating proteins, showed disease/polymorph-specific interaction patterns, possibly accounting for different resistance of patient-derived αSyn fibrils to degradation. Genetic modulation with CRISPR-based tools showed that members of the UPS degradation pathway (three E3 ligases: UBE3A, TRIM25, HUWE1 and the AAA+ ATPase VCP) reduced αSyn inclusions, in a strain-specific manner. LiP-MS also identified sets of proteins with altered protease susceptibility in postmortem brain homogenates of PD, DLB, and MSA patients. These sets were largely disease-specific and included proteins altered in cells treated with fibrils derived from patients with the matching disease. Our findings provide insight into cellular processes involved in the accumulation and turnover of αSyn pathogenic aggregates in PD, DLB and MSA in a disease specific manner and constitutes a resource of potential novel drug targets in these synucleinopathies.

Year:

2025

In Parkinson’s disease and other synucleinopathies, α-synuclein (α-Syn) misfolds and forms Ser 129 -phosphorylated aggregates (pSyn 129 ). The factors controlling this process are largely unknown. Here, we used arrayed CRISPR-mediated gene activation and ablation to discover new pSyn 129 modulators. Using quadruple-guide RNAs (qgRNAs) and Cas9, or an inactive Cas9 version fused to a synthetic transactivator, we ablated 2304 and activated 2428 human genes related to mitochondrial, trafficking and motility function in HEK293 cells. After exposure of cells to α-Syn fibrils, pSyn 129 signals were recorded by high-throughput fluorescence microscopy and aggregates were identified by image analysis. We found that pSyn 129 was increased by activating the mitochondrial protein OXR1, which decreased ATP levels and altered the mitochondrial membrane potential. Instead, pSyn 129 was reduced by ablation of the endoplasmic reticulum (ER)-associated protein EMC4, which enhanced ER-driven autophagic flux and lysosomal clearance. OXR1 activation preferentially modulated cellular reactions to fibrils derived from multiple system atrophy (MSA) patients, whereas EMC4 ablation broadly reduced pSyn 129 across diverse α-Syn polymorphs. These findings were confirmed in human iPSC-derived cortical and dopaminergic neurons, where OXR1 preferentially promoted somatic aggregation and EMC4 reduced both somatic and neuritic aggregates. These results uncover previously unrecognized roles for OXR1 and EMC4 in α-Syn aggregation, thereby broadening our mechanistic understanding of synucleinopathies.

Year:

2025

Human surgery and autopsy specimens are routinely stored as formalin-fixed paraffin-embedded (FFPE) tissue blocks. Diagnoses are based on microscopic examination of two-dimensional sections. Good clinical practice requires that samples be retained for decades, thus giving rise to vast archives of healthy and diseased tissues. While tissue clearing and whole-mount microscopy enable 3D analysis, FFPE human tissue blocks are often unsuitable for clearing and immunolabeling due to their large size, extensive cross-linking, and wax embedding. Here, we introduce ‘archival’ DISCO (aDISCO), a versatile and robust clearing method designed to overcome these challenges. aDISCO achieves complete clearing and immunolabeling of large samples stored for 15 years or more. We applied aDISCO to human brain, spinal cord, peripheral nerve, skin, muscle, heart, kidney, liver, spleen, colon, and lung, using a broad range of antibodies. To investigate the clinical usefulness of quantitative 3D histology by aDISCO, we performed a case study of focal cortical dysplasia, a neurodevelopmental disease causing epilepsy. Using deep-learning-based analysis, we found disrupted cortical layering and both focal and global neuronal density variations in FCD, features that are likely to be overlooked by conventional histology. In summary, aDISCO delivers large datasets suitable for deep-learning-based processing, enabling the detection of subtle and sparse pathologies in large archival human tissue specimens.

Year:

2025

Neurodegenerative conditions can induce the region-specific emergence of cell states relevant to their pathogenesis. To identify such phenomena, we generated a spatiotemporal transcriptomic atlas of mice infected with the RML prion strain. Thalamus and cerebellum experienced severe neuronal loss, developed intense microgliosis and, starting from 30 weeks post-inoculation, accumulated a novel microglial subpopulation characterized by strong expression of Glycoprotein non-metastatic melanoma protein B (Gpnmb). Elevated GPNMB levels were detected in the cerebrospinal fluid of sCJD patients, suggesting its possible usefulness as a biomarker of disease progression. The transcriptional profile of Gpnmb + microglia reflected a state of enhanced phagocytic activity with upregulation of genes associated with lysosomal function, including vacuolar ATPase V0 domain subunit d2 ( Atp6v0d2 ) and Galectin-3 ( Lgals3 ). In microglia-like murine BV2 cells, Gpnmb upregulation was induced by soluble find-me signals released during apoptosis, but not by apoptotic bodies or prion accumulation. Likewise, human iPSC-derived microglia showed marked upregulation of GPNMB when co-cultured with apoptotic human neurons. Gpnmb ablation impaired the ability of BV2 cells to clear apoptotic cells, underscoring its role in maintaining microglial phagocytosis. Our findings define Gpnmb ⁺ microglia as a distinct, apoptosis-driven phagocytic state, linking neuronal loss to microglial activation and positioning it as a key regulator of microglial responses to prion propagation.

Year:

2025

Heterogeneous Nuclear Ribonucleoprotein K (hnRNP K) is a limiting factor for prion propagation. However, little is known about the function of hnRNP K except that it is essential to cell survival. Here, we performed a synthetic-viability CRISPR ablation screen to identify epistatic interactors of HNRNPK . We found that deletion of Transcription Factor AP-2γ ( TFAP2C ) suppressed the death of hnRNP K-depleted LN-229 and U-251 MG cells, whereas its overexpression hypersensitized cells to hnRNP K loss. HNRNPK ablation decreased cellular ATP, downregulated genes related to lipid and glucose metabolism, and enhanced autophagy. Co-occurrent deletion of TFAP2C reversed these effects, restoring transcriptional balance and alleviating energy deficiency. We linked HNRNPK and TFAP2C interaction to mTOR signaling, observing that HNRNPK ablation inhibited mTORC1 activity through downregulation of mTOR and Rptor, while TFAP2C overexpression enhanced mTORC1 downstream functions. In prion-infected cells, TFAP2C activation reduced prion levels and countered the increased prion propagation caused by HNRNPK suppression. Short-term pharmacological inhibition of mTOR also elevated prion levels and partially mimicked the effects of HNRNPK silencing. Our study identifies TFAP2C as a genetic interactor of HNRNPK , implicates their roles in mTOR metabolic regulation, and establishes a causative link between these activities and prion propagation.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (42)

Tuomas Knowles

1920 Professor of Physical Chemistry

University of Cambridge

UNITED KINGDOM
View details

Vineet Rathod

Assistant Professor of Biochemistry

University of Lethbridge

CANADA
View details

Jesus Avila

Professor ad honorem

Consejo Superior de Investigaciones Cientificas

SPAIN
View details

Jose Lanciego

Staff Scientist & Associate Professor

Center for Applied Medical Research

SPAIN
View details

Jordi Soriano Fradera

Associate Professor

University of Barcelona

SPAIN
View details

Regina Rose Reimann

University of Zurich

SWITZERLAND
View details

Marie Egan

Professor

Yale University

UNITED STATES
View details

Christopher Glass

Professor

University of California, San Diego

UNITED STATES
View details

Silvia Sorce

University of Zurich

SWITZERLAND
View details

David Vocadlo

Professor

Simon Fraser University

CANADA
View details

Michael Ward

University of California, Berkeley

UNITED STATES
View details

Magdalini Polymenidou

-

SWITZERLAND
View details

Nikita Vladimirov

mesoSPIM developer and platform head

-

SWITZERLAND
View details

Zeynep Gümüş

Assistant Professor

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Felix Hernandez

Full Professor

Universidad Autónoma de Madrid

SPAIN
View details

Paolo Paganetti

Professor

Università della Svizzera italiana Facoltà di scienze biomediche

SWITZERLAND
View details

Amedeo Caflisch

University of Zurich

SWITZERLAND
View details

Inga Zerr

University of Göttingen

GERMANY
View details

Joel Watts

Associate Professor

University of Toronto

CANADA
View details

Stephanie C. Eisenbarth

Professor

Northwestern University Feinberg School of Medicine

UNITED STATES
View details

Pol Andrés Benito

Principal Investigator

Institut de Recerca Biomèdica de Lleida

SPAIN
View details

Daniel Kirschenbaum

Weizmann Institute of Science

ISRAEL
View details

Edward A. Fon

Professor

Montreal Neurological Institute and Hospital

CANADA
View details

Georg Meisl

Assistant Research Professor

University of Cambridge

UNITED KINGDOM
View details

Fritjof Helmchen

University of Zurich

SWITZERLAND
View details

Jiang-An Yin

Assistant professor

Tsinghua University

CHINA
View details

Alessandro Crimi

Professor

AGH University of Krakow

POLAND
View details

Mario Nuvolone

University of Pavia

ITALY
View details

Hubert Rehrauer

University of Zurich

SWITZERLAND
View details

Eleanna Kara

Assistant Professor

Rutgers University

UNITED STATES
View details

Peter Heutink

Chief Scientific Officer

Alector (United States)

UNITED STATES
View details

Marco Losa

University Hospital of Zurich

SWITZERLAND
View details

Stephanie Leeds

Assistant Professor

Yale University School of Medicine

UNITED STATES
View details

Martin Kampmann

Professor

University of California, San Francisco

UNITED STATES
View details

Anna Maria Reuss

University of Zurich

SWITZERLAND
View details

Aaron Ring

Associate Professor

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Johannes Schlachetzki

Assistant Professor

University of California, San Diego

UNITED STATES
View details

Karl Frontzek

University College London

UNITED KINGDOM
View details

Rosalina Gavín

Associate Professor

-

SPAIN
View details

Roland Martin

University of Zurich

SWITZERLAND
View details

Bernard Schneider

Senior Scientist

EPFL

SWITZERLAND
View details

Ashutosh Dhingra

Staff Scientist

Deutsches Zentrum für Neurodegenerative Erkrankungen

GERMANY
View details